Drug intelligence / Profile preview

TTX334Dx

Development stage: Preclinical
Lead developer: Temple Therapeutics

Overview

TTX334Dx is a drug candidate referenced in the context of innovative therapeutics and early diagnostics for endometriosis. It is currently in preclinical development and is being investigated as a potential treatment for endometriosis, a chronic gynecological condition characterized by the growth of endometrial tissue outside the uterus. Unlike existing treatments such as painkillers or surgery, TTX334Dx represents a novel approach; however, specific details regarding its mechanism of action, molecular target(s), or modality have not been disclosed publicly. The developer associated with this program is Temple Therapeutics[2].

Beyond the preview

Go deeper on TTX334Dx.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TTX334Dx.

Explore the full profile